A Study to Evaluate the Anti-inflammatory Effects of Solithromycin in Chronic Obstructive Pulmonary Disease

NCT ID: NCT02628769

Last Updated: 2019-12-30

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-31
• Study Completion Date: 2017-01-05

Brief Summary

This study examines the potential benefit of a new antibiotic, Solithromycin, for the long-term treatment of Chronic Obstructive Pulmonary Disease (COPD). Solithromycin is hypothesised to work by reducing inflammation in the lungs of patients with COPD. Stable COPD patients will receive treatment with solithromycin for 28 days and comparisons will be made between any effects observed with Solithromycin and a placebo. This will include any changes in inflammatory proteins, lung function and reported symptoms.

Detailed Description

Chronic obstructive pulmonary disease (COPD) is a common and debilitating respiratory illness, that kills around 30,000 people annually in the UK. The primary risk factor is cigarette smoking, which causes inflammation in the air passages of the lungs. This inflammation is irreversible and results in progressive lung destruction. Currently, there are no effective anti-inflammatory medications available for COPD.

Inhalers remain the mainstay of regular treatment for COPD. Macrolide antibiotics however, are occasionally used as a supplementary treatment for some patients. They have been shown to be anti-inflammatory. However, concerns exist over the development of bacterial resistance to such antibiotics. Consequently they are not widely prescribed for COPD. Solithromycin is a new macrolide antibiotic, which has been shown to possess superior anti-inflammatory properties. Importantly, bacteria are far less likely to develop resistance to this new medication.

The current study will assess the effect of solithromycin as an anti-inflammatory treatment for COPD. 30 patients will be recruited to receive 28 days of treatment with solithromycin or placebo, followed by a 28 day wash out period (no study medication), before taking a further 28 days of treatment (the medication not taken first time around, i.e. either solithromycin or placebo). This study is a single-centre (Harefield Hospital), double-blind (study team and patient are not told what treatment they are taking), randomised (order in which solithromycin and placebo are taken), placebo-controlled and has a crossover design (subjects take both solithromycin and placebo separately). Sputum, blood and fluid from the nasal lining will be periodically sampled to examine any effect on the levels of inflammatory cells and proteins during the study. Any changes in lung function parameters or symptoms (COPD Assessment Test) will also be assessed.

Conditions

Pulmonary Disease, Chronic Obstructive

Keywords

Solithromycin; Chronic Obstructive Pulmonary Disease; Inflammation; Macrolide

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Solithromycin

28 day treatment of 400 mg Solithromycin taken once a day.

Group Type: EXPERIMENTAL

Solithromycin

Intervention Type: DRUG

Placebo

28 day treatment with placebo taken once per day.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

Solithromycin

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

CEM-101

Eligibility Criteria

Inclusion Criteria

1. History of cigarette smoking >10 pack-years.

2. Post-bronchodilator FEV1/FVC of <0.70 and FEV1 of 30-79% of predicted normal value.

3. Patients on prescribed inhaled corticosteroids can be enrolled.

4. Females of non-childbearing potential: surgically sterile (e.g. tubal ligation) or at least 2 years post-menopausal.

5. Females of childbearing potential (including females less than 2 years post-menopausal) must have a negative pregnancy test at enrollment and must agree to use highly effective methods of birth control (i.e. diaphragm plus spermicide or male condom plus spermicide, oral contraceptive in combination with a second method, contraceptive implant, injectable contraceptive, indwelling intrauterine device, sexual abstinence, or a vasectomized partner) while participating in the study and for 30 days after the last dose of study drug.

6. The patient must be willing and able to comply with all study visits and procedures.

7. The patient must be a suitable candidate for oral therapy and be able to swallow capsules intact.

8. The patient must provide written informed consent.

9. No evidence of active bacterial infection in sputum by qPCR evaluation.

Exclusion Criteria

1. Acute exacerbation of COPD within the previous 60 days or during the washout period of the study.

2. Any condition that could possibly affect oral drug absorption, e.g. gastroenteritis, status post gastrectomy, status post bariatric surgery.

3. Currently taking medication for HIV, chronic hepatitis B, or hepatitis C virus (HCV) infection.

4. Currently taking theophylline or other xanthine medication.

5. Currently taking warfarin.

6. Known concomitant infection (pulmonary or otherwise) which would require additional systemic antibiotics.

7. QTc greater than 450 msec for males or females as corrected by the Fridericia formula.

8. Current use of drugs known to prolong the QT interval, including Class Ia (quinidine, procainamide) or Class III (amiodarone, sotalol) antiarrhythmics.

9. Concomitant use of drugs, foods, or herbal products known to be moderate to potent inhibitors of CYP3A4 isozymes: oral antifungal agents (e.g. ketoconazole, itraconazole, posaconazole, fluconazole and voriconazole); HIV protease inhibitors (e.g. ritonavir and saquinavir), HCV protease inhibitors (e.g. boceprevir and telaprevir), nefazodone, fluvoxamine, conivaptan, diltiazem, verapamil, aprepitant, ticlopidine, crizotinib, imatinib; grapefruit or grapefruit juice.

10. Any use within the prior 7 days of drugs or herbal products known to be moderate to potent inducers of CYP3A4 isozymes: St. John's Wort, rifampin, rifabutin, anti-convulsants (e.g. phenobarbital, carbamazepine, phenytoin, rufinamide), modafinil, armodafinil, etraverine, efavirenz, bosentan.

11. Required current use of drugs with narrow therapeutic indices that are principally metabolized by CYP3A4 or transported by P-glycoprotein (P-gp), for which a drug interaction with solithromycin could result in higher and possibly unsafe exposures to these drugs: e.g. the P-gp substrates digoxin or colchicine and the CYP3A4 substrates alfentanil, astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, fentanyl, midazolam, pimozide, quinidine, sirolimus, tacrolimus, everolimus, and terfenadine).

12. History of organ transplant.

13. Cytotoxic chemotherapy or radiation therapy within the previous 3 months.

14. Known neuromuscular disorder from clinical history (e.g. myasthenia gravis, Parkinson's disease).

15. Known significant renal, hepatic, or hematologic impairment.

16. Women who are pregnant or breast feeding

17. Prior participation in this protocol.

18. Any investigational drugs taken or investigational devices used within 4 weeks before administration of the first dose of the study drug.

19. History of intolerance or hypersensitivity to macrolide antibiotics.

20. Any concomitant condition that, in the opinion of the Investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy and follow-up could be completed (e.g. life expectancy <30 days).

• Minimum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Melinta Therapeutics, Inc.

INDUSTRY

Sponsor Role: collaborator

Imperial College London

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peter J Barnes, FRS, FMedSci

Role: PRINCIPAL_INVESTIGATOR

Imperial College London

William Man, MBBS, PhD

Role: STUDY_CHAIR

Royal Brompton & Harefield NHS Foundation Trust

Locations

Muscle Lab, Respiratory Medicine, Harefield Hospital

Harefield, Middlesex, United Kingdom

Countries

United Kingdom

Other Identifiers

2014-003077-42

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

14/LO/2066

Identifier Type: OTHER

Identifier Source: secondary_id

CE01-204

Identifier Type: -

Identifier Source: org_study_id